RU2002121771A - Композиции и способы для терапии и диагностики рака предстательной железы - Google Patents
Композиции и способы для терапии и диагностики рака предстательной железыInfo
- Publication number
- RU2002121771A RU2002121771A RU2002121771/13A RU2002121771A RU2002121771A RU 2002121771 A RU2002121771 A RU 2002121771A RU 2002121771/13 A RU2002121771/13 A RU 2002121771/13A RU 2002121771 A RU2002121771 A RU 2002121771A RU 2002121771 A RU2002121771 A RU 2002121771A
- Authority
- RU
- Russia
- Prior art keywords
- patient
- sequences
- seq
- sequence
- polypeptide
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 239000000203 mixture Substances 0.000 title claims 4
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000006853 reporter group Chemical group 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48367200A | 2000-01-14 | 2000-01-14 | |
| US09/483,672 | 2000-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002121771A true RU2002121771A (ru) | 2004-03-10 |
Family
ID=23921037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002121771/13A RU2002121771A (ru) | 2000-01-14 | 2001-01-16 | Композиции и способы для терапии и диагностики рака предстательной железы |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1261708A2 (no) |
| JP (1) | JP2003528591A (no) |
| KR (1) | KR20030016217A (no) |
| CN (1) | CN1436234A (no) |
| AU (1) | AU3447401A (no) |
| BR (1) | BR0107643A (no) |
| CA (1) | CA2397741A1 (no) |
| CZ (1) | CZ20022756A3 (no) |
| HU (1) | HUP0203968A3 (no) |
| IL (1) | IL150732A0 (no) |
| MX (1) | MXPA02006934A (no) |
| NO (1) | NO20023402L (no) |
| PL (1) | PL356908A1 (no) |
| RU (1) | RU2002121771A (no) |
| WO (1) | WO2001051633A2 (no) |
| ZA (1) | ZA200206400B (no) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030125536A1 (en) * | 1996-01-11 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US7202342B1 (en) | 1999-11-12 | 2007-04-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6620922B1 (en) | 1997-02-25 | 2003-09-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6329505B1 (en) | 1997-02-25 | 2001-12-11 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| US7517952B1 (en) | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6630305B1 (en) | 1999-11-12 | 2003-10-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6818751B1 (en) | 1997-08-01 | 2004-11-16 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6465611B1 (en) | 1997-02-25 | 2002-10-15 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US6759515B1 (en) | 1997-02-25 | 2004-07-06 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6800746B2 (en) | 1997-02-25 | 2004-10-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6894146B1 (en) | 1997-02-25 | 2005-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6943236B2 (en) | 1997-02-25 | 2005-09-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US7033827B2 (en) | 1997-02-25 | 2006-04-25 | Corixa Corporation | Prostate-specific polynucleotide compositions |
| US6613872B1 (en) | 1997-02-25 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US7008765B1 (en) | 1997-04-10 | 2006-03-07 | The Johns Hopkins University | PCA3, PCA3 genes, and methods of use |
| US6861215B1 (en) | 1998-05-21 | 2005-03-01 | Diadexus, Inc. | Method of diagnosing, monitoring, and staging prostate cancer |
| US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
| DE69941187D1 (de) | 1998-06-01 | 2009-09-10 | Agensys Inc | Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen |
| US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6902892B1 (en) | 1998-10-19 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| US7022497B1 (en) | 1999-03-11 | 2006-04-04 | Mt. Sinai Hospital | Human kallikrein-like genes |
| US6943235B1 (en) | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
| DK1222266T3 (da) | 1999-09-29 | 2006-07-10 | Diagnocure Inc | PCA3-messenger-RNA i benigne og maligne prostatavæv |
| US6790631B1 (en) | 1999-10-05 | 2004-09-14 | Agensys, Inc. | G protein-coupled receptor up-regulated in prostate cancer and uses thereof |
| US7361338B2 (en) | 1999-10-05 | 2008-04-22 | Agensys, Inc. | Methods to inhibit growth of prostate cancer cells |
| AU779846B2 (en) * | 1999-10-07 | 2005-02-17 | Corixa Corporation | Methods of using a mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of heterologous proteins |
| US20020048777A1 (en) | 1999-12-06 | 2002-04-25 | Shujath Ali | Method of diagnosing monitoring, staging, imaging and treating prostate cancer |
| CA2403909A1 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| WO2001098460A2 (en) | 2000-06-20 | 2001-12-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| AU2001281322A1 (en) * | 2000-07-13 | 2002-01-30 | Biogen, Inc. | Methods of identifying renal protective factors |
| US7205108B2 (en) | 2000-07-28 | 2007-04-17 | Ulrich Wissenbach | Trp8, Trp9 and Trp10, novel markers for cancer |
| US7048931B1 (en) | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| EP1573024A4 (en) | 2001-04-10 | 2007-08-29 | Agensys Inc | NUCLEIC ACIDS AND SUITABLE PROTEINS SUITABLE FOR THE TREATMENT AND EVIDENCE OF VARIOUS CANCER DISEASES |
| CA2446788A1 (en) * | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| US6897024B2 (en) | 2001-05-31 | 2005-05-24 | Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen | Nucleic acid molecules comprising the promoter for PCA3, and uses thereof |
| KR100628425B1 (ko) | 2001-06-20 | 2006-09-28 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| US20050272120A1 (en) | 2001-06-20 | 2005-12-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| ES2537074T3 (es) | 2001-09-06 | 2015-06-02 | Agensys, Inc. | Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer |
| US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| AU2003210663A1 (en) | 2002-01-25 | 2003-09-02 | The Regents Of The University Of California | Methods of modulating cold sensory perception |
| DE10215321A1 (de) * | 2002-04-02 | 2003-10-23 | Metagen Pharmaceuticals Gmbh | Trp-p8 Splice Varianten und regulatorische RNA |
| NZ537125A (en) * | 2002-06-11 | 2006-08-31 | Glaxosmithkline Biolog S | Immunogenic compositions |
| DE10234901A1 (de) * | 2002-07-26 | 2004-02-12 | Metagen Pharmaceuticals Gmbh | Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| AU2004209578A1 (en) | 2003-02-07 | 2004-08-19 | Diagnocure Inc. | Method to detect prostate cancer in a sample |
| PT1742966E (pt) | 2004-04-22 | 2014-02-05 | Agensys Inc | Anticorpos e moléculas derivadas daí que se ligam às proteínas steap-1 |
| CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
| EP1916298B1 (en) * | 2005-06-14 | 2011-12-28 | Dnavec Corporation | Methods for producing monoclonal antibodies |
| PL2845866T3 (pl) | 2006-10-27 | 2017-10-31 | Genentech Inc | Przeciwciała i immunokoniugaty oraz ich zastosowanie |
| CN104718284A (zh) * | 2012-05-25 | 2015-06-17 | 塞勒克提斯公司 | 工程化用于免疫疗法的异体和免疫抑制耐受性t细胞的方法 |
| CN104357451B (zh) * | 2014-12-02 | 2016-09-21 | 广州市番禺区中心医院 | 针对dd3基因的小干扰rna及其表达载体构建与应用 |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201520566D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| SI3558339T1 (sl) * | 2016-12-22 | 2024-05-31 | Cue Biopharma, Inc. | Celico T modulirajoči multimerni polipeptidi in postopki njihove uporabe |
| WO2018184966A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Antibodies binding to steap-1 |
| CN110988348B (zh) * | 2019-11-06 | 2022-07-05 | 北京九强生物技术股份有限公司 | 游离前列腺特异性抗原检测试剂盒及其制备方法 |
| CN114250238B (zh) * | 2021-11-26 | 2023-08-25 | 北京航空航天大学 | 基因编码的神经元发育调控多肽及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU728186B2 (en) * | 1996-03-15 | 2001-01-04 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
| CN1195851C (zh) * | 1997-02-25 | 2005-04-06 | 科里克萨有限公司 | 用于前列腺癌免疫疗法的化合物及其用途 |
| EP1630235A3 (en) * | 1997-02-25 | 2009-05-27 | Corixa Corporation | Compounds for immunodiagnosis of prostate cancer and method for their use |
| TR200100916T2 (no) * | 1998-07-14 | 2002-06-21 | Corixa@@Corporation | |
| AU7994200A (en) * | 1999-10-04 | 2001-05-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| WO2001034802A2 (en) * | 1999-11-12 | 2001-05-17 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
-
2001
- 2001-01-16 CA CA002397741A patent/CA2397741A1/en not_active Abandoned
- 2001-01-16 EP EP01906582A patent/EP1261708A2/en not_active Withdrawn
- 2001-01-16 MX MXPA02006934A patent/MXPA02006934A/es unknown
- 2001-01-16 BR BR0107643-4A patent/BR0107643A/pt not_active Application Discontinuation
- 2001-01-16 WO PCT/US2001/001574 patent/WO2001051633A2/en not_active Application Discontinuation
- 2001-01-16 CZ CZ20022756A patent/CZ20022756A3/cs unknown
- 2001-01-16 RU RU2002121771/13A patent/RU2002121771A/ru unknown
- 2001-01-16 CN CN01806526A patent/CN1436234A/zh active Pending
- 2001-01-16 HU HU0203968A patent/HUP0203968A3/hu unknown
- 2001-01-16 IL IL15073201A patent/IL150732A0/xx unknown
- 2001-01-16 KR KR1020027009144A patent/KR20030016217A/ko not_active Application Discontinuation
- 2001-01-16 PL PL01356908A patent/PL356908A1/xx unknown
- 2001-01-16 JP JP2001551207A patent/JP2003528591A/ja active Pending
- 2001-01-16 AU AU34474/01A patent/AU3447401A/en not_active Abandoned
-
2002
- 2002-07-15 NO NO20023402A patent/NO20023402L/no not_active Application Discontinuation
- 2002-08-12 ZA ZA200206400A patent/ZA200206400B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001051633A9 (en) | 2002-10-31 |
| AU3447401A (en) | 2001-07-24 |
| WO2001051633A2 (en) | 2001-07-19 |
| CZ20022756A3 (cs) | 2003-02-12 |
| EP1261708A2 (en) | 2002-12-04 |
| MXPA02006934A (es) | 2003-01-28 |
| PL356908A1 (en) | 2004-07-12 |
| BR0107643A (pt) | 2003-06-10 |
| NO20023402L (no) | 2002-08-29 |
| CA2397741A1 (en) | 2001-07-19 |
| IL150732A0 (en) | 2003-02-12 |
| HUP0203968A3 (en) | 2004-09-28 |
| NO20023402D0 (no) | 2002-07-15 |
| HUP0203968A2 (hu) | 2003-03-28 |
| WO2001051633A3 (en) | 2002-06-20 |
| KR20030016217A (ko) | 2003-02-26 |
| JP2003528591A (ja) | 2003-09-30 |
| ZA200206400B (en) | 2004-01-21 |
| CN1436234A (zh) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002121771A (ru) | Композиции и способы для терапии и диагностики рака предстательной железы | |
| JP6268129B2 (ja) | 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用 | |
| Walter et al. | Antibodies specific for the carboxy-and amino-terminal regions of simian virus 40 large tumor antigen. | |
| JP2005504513A5 (no) | ||
| JP2006515749A5 (no) | ||
| RU2002130715A (ru) | Композиции и способы терапии и диагностики рака молочной железы | |
| Wakabayashi et al. | Immunospecificity of nonhistone proteins in chromatin | |
| JP2004512824A5 (no) | ||
| KR20150132479A (ko) | 복합 유전자 세트에서의 독특하게 태그되고 재배열된 적응 면역 수용체 유전자 | |
| KR20140039318A (ko) | 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자 | |
| CA2269634A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
| US20090324596A1 (en) | Methods of identifying and treating poor-prognosis cancers | |
| US20200300857A1 (en) | Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy | |
| WO2003037267B1 (en) | Compositions and methods for the therapy and diagnosis of lung cancer | |
| CN115698081A (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
| Gorski et al. | Serological and immunochemical analysis of the products of a single HLA DR-alpha and DR-beta chain gene expressed in a mouse cell line after DNA-mediated cotransformation reveals that the beta chain carries a known supertypic specificity. | |
| CA2325605A1 (en) | Isolated peptides corresponding to amino acid sequences of ny-eso-1, wherein said peptides bind to mhc class i and mhc class ii molecules, and uses thereof | |
| JPH11514859A (ja) | 肝腫瘍性疾患に関連する遺伝子 | |
| CA2287571A1 (en) | Reagents and methods useful for detecting diseases of the prostate | |
| CA2232237A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
| WO2021056025A2 (en) | Anti-epha10 antibodies and methods of use thereof | |
| RU2002128922A (ru) | Композиции и способы для лечения и диагностики рака легких | |
| Pyles et al. | Novel protein isoforms of the APC tumor suppressor in neural tissue | |
| CN113412130A (zh) | 用于诊断和治疗癌症及其他疾病的对促肿瘤癌症相关成纤维细胞的识别和靶向 | |
| CN113980143B (zh) | 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用 |